V
47.71
-1.67 (-3.38%)
| Penutupan Terdahulu | 49.38 |
| Buka | 48.99 |
| Jumlah Dagangan | 1,030,082 |
| Purata Dagangan (3B) | 987,587 |
| Modal Pasaran | 3,771,436,032 |
| Harga / Pendapatan (P/E TTM) | 125.55 |
| Harga / Pendapatan (P/E Ke hadapan) | 31.65 |
| Harga / Jualan (P/S) | 7.66 |
| Harga / Buku (P/B) | 2.98 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | 7.13% |
| Margin Operasi (TTM) | 7.03% |
| EPS Cair (TTM) | 0.420 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 18.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.23% |
| Nisbah Semasa (MRQ) | 5.10 |
| Aliran Tunai Operasi (OCF TTM) | 89.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 76.93 M |
| Pulangan Atas Aset (ROA TTM) | 1.94% |
| Pulangan Atas Ekuiti (ROE TTM) | 2.86% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Bercampur |
| Diagnostics & Research (Global) | Menaik | Bercampur | |
| Stok | Veracyte, Inc. | Menaik | Menaik |
AISkor Stockmoo
-1.0
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 4.0 |
| Purata | -1.00 |
|
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.54% |
| % Dimiliki oleh Institusi | 107.98% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 48.00 (Morgan Stanley, 0.61%) | Jual |
| 48.00 (UBS, 0.61%) | Beli | |
| Median | 45.00 (-5.68%) | |
| Rendah | 43.00 (Canaccord Genuity, -9.87%) | Pegang |
| Purata | 45.50 (-4.63%) | |
| Jumlah | 4 Beli, 1 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 44.40 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 02 Dec 2025 | 48.00 (0.61%) | Jual | 46.39 |
| 11 Nov 2025 | 40.00 (-16.16%) | Jual | 42.66 | |
| Canaccord Genuity | 05 Nov 2025 | 43.00 (-9.87%) | Pegang | 46.04 |
| 20 Oct 2025 | 40.00 (-16.16%) | Pegang | 36.65 | |
| Guggenheim | 05 Nov 2025 | 45.00 (-5.68%) | Beli | 46.04 |
| Needham | 05 Nov 2025 | 44.00 (-7.78%) | Beli | 46.04 |
| UBS | 05 Nov 2025 | 48.00 (0.61%) | Beli | 46.04 |
| Freedom Capital Markets | 17 Oct 2025 | 45.00 (-5.68%) | Beli | 35.83 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| JONES EVAN/ FA | - | 49.38 | -1,106 | -54,614 |
| LEITE JOHN | - | 49.38 | -2,808 | -138,659 |
| Jumlah Keseluruhan Kuantiti Bersih | -3,914 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -193,273 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 49.38 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LEITE JOHN | Pegawai | 25 Nov 2025 | Jual automatik (-) | 2,808 | 49.38 | 138,659 |
| JONES EVAN/ FA | Pengarah | 25 Nov 2025 | Jual automatik (-) | 1,106 | 49.38 | 54,614 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Nov 2025 | Pengumuman | Veracyte to Participate in Upcoming Investor Conferences |
| 04 Nov 2025 | Pengumuman | Veracyte Announces Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Pengumuman | Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing |
| 15 Oct 2025 | Pengumuman | Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025 |
| 28 Sep 2025 | Pengumuman | Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer |
| 24 Sep 2025 | Pengumuman | Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025 |
| 09 Sep 2025 | Pengumuman | Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |